UM-1
Role
UM-1 will be the leader of WP7 . UM-1 will thus organize and oversee the quality control of all laboratory aspects of the study. This will include CareHPV testing, HPV DNA testing, cytology, histology, HIV and STI results. To this end UM-1 will organize standardised training of African Partners, regular supervision, supply of proficiency panels and will write the SOPs to undertake testing and will carry out repeat testing to a specified number of tests depending on test. In addition, the Virology laboratory of UM-1 will undertake the timely testing of HR-HPV genotypes in samples from Burkina Faso; whilst the pathology laboratory will perform cytology and histology quality control, as well as coordinate the Study Endpoints Committee, which will comprise of all the pathologists in the HARP study.
Key personnel
Dr Nicolas Nagot MD PhD, Site PI & Co-investigator: a clinical epidemiologist at U1058 who will coordinate UM-1 inputs for the Consortium regarding study design and implementation with particular reference to the Burkina Faso site (CRIS-UO). He will participate in the design, planning and implementation of the study, will be involved in overseeing the quality control testing and will help conduct analyses and dissemination of results.
Dr Michel Segondy PhD, Laboratory Lead & Co-investigator: he heads the Virology laboratory at UM-1/U1058 will oversee the quality control of
CareHPV
testing at study sites, all HPV genotyping testing, and HPV variant testing and analysis. He is leading WP7.
Dr Marie Noëlle Didelot-Rousseau MB PhD, Co-investigator: a post-doctoral research scientist at U1058 specialising in HPV research, she will conduct the initial training and provide on-site supervision where required for
CareHPV
(and possibly HPV genotyping) in Burkina Faso and South Africa. She will be directly in charge of performing the HR-HPV genotyping on project samples and QC testing of
CareHPV
and HPV genotype testing.
Dr Valerie Costes MD, Co-investigator: she is a Senior Pathologist who will provide training, supervision and quality control for cytological and pathological samples from both sites and will chair the Study Endpoints Committee.
Dr Sylviane Doutre MD, Senior Pathologist: who is from the Montpellier University Hospital. She is involved in the HARP project for quality controls in cytology and histology and in capacity building.
Nicolas Leventoux, Cytotechnician: he graduated from the ESTAC School with 10 years of experience in both private and state-run laboratories. He is a co-writer of the SOPs in cytology and histology for Burkina Faso and an instructor for those procedures in Ouagadougou.
Dr Jean Ngou PhD, Lab Technician: who is involved in HPV testing and genotyping.
Ms Cara Chan Manville, Site Project Administrator: who will oversee the finance and administration of the study.
